Palvella Therapeutics (PVLA) Other Accumulated Expenses (2013 - 2026)

Palvella Therapeutics (PVLA) has reported Other Accumulated Expenses for 14 consecutive years, with $960000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 29.38% year-over-year to $960000.0; the TTM figure through Mar 2026 stood at $960000.0 (up 29.38% YoY), while the FY2025 annual figure was $705000.0, down 40.71% from the prior year.
• Other Accumulated Expenses improved to $960000.0 in Q1 2026 per PVLA's latest filing, from $705000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $1.2 million in Q4 2024 and bottomed at $120000.0 in Q4 2023.
• Historically, Other Accumulated Expenses has averaged $711176.5 across 5 years, with a median of $637000.0 in 2022.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses plunged 75.16% — and 2024, when it surged 890.83%.
• Palvella Therapeutics' Other Accumulated Expenses stood at $483000.0 in 2022, then slumped by 75.16% to $120000.0 in 2023, then soared by 890.83% to $1.2 million in 2024, then slumped by 40.71% to $705000.0 in 2025, then jumped by 36.17% to $960000.0 in 2026.
• Business Quant data shows PVLA's Other Accumulated Expenses at $960000.0 in Q1 2026, $705000.0 in Q4 2025, and $1.1 million in Q3 2025.